Should I buy Johnson & Johnson (JNJ) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $294 (+18 %), call made on July 17, 2026, maturing on July 17, 2027 (89 d ago).
Firm-by-firm track record on Johnson & Johnson
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 86 % | +29.0 % | 7 | $320 +29% |
| RBC Capital | 83 % | +18.9 % | 23 | $290 +17% |
| Citigroup | 61 % | +13.2 % | 18 | $303 +22% |
| Barclays | 100 % | +11.4 % | 5 | $255 +3% |
| Morgan Stanley | 100 % | +11.1 % | 5 | $294 +18% |
| Wells Fargo | 90 % | +9.9 % | 10 | $282 +13% |
| Raymond James | 65 % | +7.5 % | 23 | $265 +7% |
| Cantor Fitzgerald | 80 % | +3.6 % | 40 | $215 -14% |
✅ Reasons to believe
- 83% of analysts rate it a buy (Buy consensus, 12 ratings) — a sign of market conviction.
- Median price target $289, i.e. +16% from the current price ($249).
- The most reliable firm on JNJ, Barclays (100% hit rate, 5 scored calls), targets $255 (call made on April 15, 2026, maturing on April 15, 2027) (+3%) in its most recent call, and $197 (call made on December 2, 2025, maturing on December 2, 2026) (-21%) in the one coming due soonest.
- 6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.1% yield), raised for 23 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 12 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on JNJ
Median target $289 (+16%) · 12 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Johnson & Johnson now?
We won't decide for you. The facts: 83% of analysts rate it a buy, median target $289 (+16%), and Barclays (most reliable on JNJ, 100%) targets $255. Weigh that against valuation (P/E ~29). This is not personalized advice.
Is it too late to invest in Johnson & Johnson?
Not according to analysts: the median target ($289) is still +16% above the current price ($249) (most reliable on JNJ: Barclays, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Johnson & Johnson still worth investing in?
It depends on the gap between the price ($249) and its estimated value: analysts target $289 on median (+16%), with 83% buys (most reliable on JNJ: Barclays, 100%). Cross-check with their real reliability on JNJ and the cautions above. Information, not advice.
What's the main risk in buying JNJ?
The consensus is not unanimous: of 12 ratings, 2 are neutral.
→ Go deeper: the full Johnson & Johnson profile (consensus, analyst reliability, price target, performance).